On 8 November 2016, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) has finished it’s A-share non-public offering.  This offering has raised nearly RMB 2.3 billion from China Life Insurance, Taikang Assets and Anhui Railway Development Group, and the sponsor and underwriter are UBS Securities and Tebon Securities, respectively.

This non-public offering was approved in July and completed in November 2016. Grandall Shanghai Office acted as the adviser of Fosun Pharma, with partners Ms. WU Xiaoliang, Ms. WEI Wei and Mr. ZHOU Yijie, and their team providing overall legal service in the project.